Literature DB >> 31481497

Syndecan-Mediated Ligation of ECM Proteins Triggers Proliferative Arrest of Disseminated Tumor Cells.

Tsukasa Shibue1,2, Ferenc Reinhardt1, Robert A Weinberg3,2,4.   

Abstract

Systemic dissemination of tumor cells often begins long before the development of overt metastases, revealing the inefficient nature of the metastatic process. Thus, already at the time of initial clinical presentation, many patients with cancer harbor a myriad disseminated tumor cells (DTC) throughout the body, most of which are found as mitotically quiescent solitary cells. This indicates that the majority of DTCs fail, for still unknown reasons, to initiate rapid proliferation after entering foreign tissue, which likely contributes significantly to the inefficiency of metastasis formation. Here, we showed that extracellular matrix (ECM) components of the host parenchyma prevented proliferation of DTCs that had recently infiltrated foreign tissue by binding to syndecan receptors expressed on the surface of these cells. This led to the recruitment of the Par-3:Par-6:atypical PKC protein complex, a critical regulator of cell polarity, to the plasma membrane and release of Par-1 kinase into the cytosol. Cytosolic Par-1 bound, phosphorylated, and inactivated KSR scaffolding proteins ultimately inhibited Ras/ERK signaling and, in turn, cell proliferation. Inhibition of the syndecan-mediated signaling restored the proliferation of otherwise dormant DTCs, enabling these cells to efficiently colonize foreign tissues. Intriguingly, naturally aggressive cancer cells overcame the antiproliferative effect of syndecan-mediated signaling either by shutting down this signaling pathway or by activating a proproliferative signaling pathway that works independent of syndecan-mediated signaling. Collectively, these observations indicate that the proliferative arrest of DTCs is attributable, in part, to the syndecan-mediated ligation of ECM proteins. SIGNIFICANCE: This study identifies a novel signaling pathway that regulates the proliferative dormancy of individual disseminated tumor cells.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/79/23/5944/F1.large.jpg. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31481497      PMCID: PMC7685526          DOI: 10.1158/0008-5472.CAN-19-1165

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

Review 1.  Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.

Authors:  Gary L Johnson; Razvan Lapadat
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

2.  C-TAK1 regulates Ras signaling by phosphorylating the MAPK scaffold, KSR1.

Authors:  J Müller; S Ory; T Copeland; H Piwnica-Worms; D K Morrison
Journal:  Mol Cell       Date:  2001-11       Impact factor: 17.970

3.  The molecular scaffold kinase suppressor of Ras 1 is a modifier of RasV12-induced and replicative senescence.

Authors:  Robert L Kortum; Heidi J Johnson; Diane L Costanzo; Deanna J Volle; Gina L Razidlo; Angela M Fusello; Andrey S Shaw; Robert E Lewis
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

4.  Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy.

Authors:  George N Naumov; Ian C MacDonald; Pascal M Weinmeister; Nancy Kerkvliet; Kishore V Nadkarni; Sylvia M Wilson; Vincent L Morris; Alan C Groom; Ann F Chambers
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

5.  The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites.

Authors:  Hua Gao; Goutam Chakraborty; Ai Ping Lee-Lim; Qianxing Mo; Markus Decker; Alin Vonica; Ronglai Shen; Edi Brogi; Ali H Brivanlou; Filippo G Giancotti
Journal:  Cell       Date:  2012-08-17       Impact factor: 41.582

6.  Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton.

Authors:  Dalit Barkan; Hynda Kleinman; Justin L Simmons; Holly Asmussen; Anil K Kamaraju; Mark J Hoenorhoff; Zi-yao Liu; Sylvain V Costes; Edward H Cho; Stephen Lockett; Chand Khanna; Ann F Chambers; Jeffrey E Green
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

7.  Loss of the Par3 polarity protein promotes breast tumorigenesis and metastasis.

Authors:  Luke Martin McCaffrey; JoAnne Montalbano; Constantina Mihai; Ian G Macara
Journal:  Cancer Cell       Date:  2012-11-13       Impact factor: 31.743

8.  Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells.

Authors:  Ilya Serebriiskii; Remedios Castelló-Cros; Acacia Lamb; Erica A Golemis; Edna Cukierman
Journal:  Matrix Biol       Date:  2008-03-06       Impact factor: 11.583

Review 9.  Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling.

Authors:  Christopher J Caunt; Stephen M Keyse
Journal:  FEBS J       Date:  2012-08-28       Impact factor: 5.542

10.  Regulation of glucose homeostasis by KSR1 and MARK2.

Authors:  Paula J Klutho; Diane L Costanzo-Garvey; Robert E Lewis
Journal:  PLoS One       Date:  2011-12-19       Impact factor: 3.240

View more
  3 in total

1.  Sustained Oncogenic Signaling in the Cytostatic State Enables Targeting of Nonproliferating Persistent Cancer Cells.

Authors:  Lisa M Kim; Paul Y Kim; Yemarshet K Gebreyohannes; Cheuk T Leung
Journal:  Cancer Res       Date:  2022-09-02       Impact factor: 13.312

2.  Stromal-Derived Extracellular Vesicles Suppress Proliferation of Bone Metastatic Cancer Cells Mediated by ERK2.

Authors:  Alison B Shupp; Manish Neupane; Lebaron C Agostini; Gang Ning; Jonathan R Brody; Karen M Bussard
Journal:  Mol Cancer Res       Date:  2021-05-21       Impact factor: 5.852

Review 3.  Syndecan-1 (CD138), Carcinomas and EMT.

Authors:  John R Couchman
Journal:  Int J Mol Sci       Date:  2021-04-19       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.